Drug Profile
NanoLymph-3
Alternative Names: NanoLymphLatest Information Update: 18 Sep 2006
Price :
$50
*
At a glance
- Originator Sanofi Winthrop
- Class Contrast media
- Mechanism of Action Radiography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 18 Sep 2006 Discontinued - Phase-II for Cancer (diagnosis) in European Union (unspecified route)
- 18 Sep 2006 Discontinued - Phase-II for Cancer (diagnosis) in USA (unspecified route)
- 18 Sep 2006 Discontinued - Preclinical for Cancer (diagnosis) in Japan (unspecified route)